Citations

Clear

16281 citation(s) found for "Yu, David".

Long‐term outcomes of renal AL amyloidosis patients undergoing autologous stem cell transplantation: Validating the performance of the renal staging system
Muchtar, Eli , Gertz, Morie A. , Mwangi, Raphael , Hassan, Hamza , Leung, Nelson , Dingli, David , Sanchorawala, Vaishali , Dispenzieri, Angela , Leung, Nelson , Sanchorawala, Vaishali , Gertz, Morie A , Muchtar, E , Dingli, David , Hassan, Hamza , Dispenzieri, Angela , Buadi, Francis K. , Staron, Andrew

Mayo Clinic

American Journal of Hematology | August 29, 2024 | Volume: 99 | Issue: 11 | Pages: 2118-2126

10.1002/ajh.27460 | PMID 39207186 Get It

AbstractRenal AL amyloidosis can be complicated by end‐stage renal disease (ESRD) requiring renal replacement therapy (RRT). In this study, we describe the long‐term outcomes of renal AL amyloidosis patients undergoing autologous stem cell transplantation (ASCT) and assess the utility of the renal staging system. Retrospective study of renal AL patients (n = 697; Mayo Clinic, Boston University) who underwent ASCT between 2003 and 2020. Renal stage was assigned based on 24‐h proteinuria and estimated glomerular filtration rate measurements. Renal survival was defined as the time from ASCT until initiation of RRT, while patients who were not placed on RRT were censored at their last follow‐up. With a median follow‐up of 10.4 years, RRT was required in 149 patients (21%). The median time from ASCT to ESRD was 3.4 years, with late events of progression to ESRD seen >10 years from ASCT. Pre‐ASCT renal stage was significantly associated with the cumulative incidence of RRT: 3‐year RRT rate was 3%, 10%, and 37% for renal stages I, II, and III, respectively. However, in the 2012–2020 period subset, a significant decrease in ESRD risk was noted across all renal stages (3‐year RRT 0%, 5%, and 24%, respectively). In multivariate analysis, renal survival was independently associated with the pre‐ASCT renal stage, lambda isotype, bone marrow plasmacytosis ≥20%, post‐ASCT hematologic response, and year of ASCT. Long‐term outcomes of renal AL amyloidosis treated with ASCT are presented. Renal stage reliably predicts renal outcomes in patients with AL undergoing ASCT, despite a reduction in the proportion of patients progressing to RRT in recent years.
Comparison of 2 Free Light Chain Assays: Performance of the Free Light Chain Ratio as a Risk Factor for MGUS Progression
Andress, Benjamin , Coker, Jonathan, Dasari, Surendra , Murray, David , Willrich, Maria Alice V. , Andress, Benjamin D, Pazdernik, Vanessa M K, Larson, Dirk R. , Coker, Jonathan D, Rajkumar, Vincent, Murray, David L , Willrich, Maria A , Wang, Qian , Pazdernik, Vanessa , Rajkumar, S. Vincent , Dispenzieri, Angela

Mayo Clinic

Clinical Chemistry | August 29, 2024 | Volume: 70 | Issue: 10 | Pages: 1268-1278

10.1093/clinchem/hvae124 | PMID 39206639 Get It

Abstract Background New immunoglobulin free light chain (FLC) assays are available. Despite analytical differences, it seems possible to use free light chain ratios (FLCr) generated by different assays and apply similar cut-points for the diagnosis of multiple myeloma. It is still unknown if we can use different assays for risk stratification of patients with monoclonal gammopathy of undetermined significance (MGUS). Methods Patients diagnosed with MGUS (N = 923) had FLC tested using a nephelometric FreeLite (Binding Site) assay on BNII instruments (Siemens) and a Sebia FLC assay (Sebia) on a DS2 ELISA analyzer (Dynex). Patients were followed up for progression to any plasma cell dyscrasia (PCD) for several decades. The Mayo MGUS risk stratification model for progression was assessed with both assays (M-spike >1.5 g/dL; non-IgG isotype and abnormal FLCr), using package insert reference intervals (RI) and a new metric called principal component 2 (PC2). Results There were 94 events of progression to PCD in the cohort during a median of 38 years of follow-up. Freelite and Sebia FLC showed similar hazard ratios in the risk models for elevated FLCr. An alternative clinical decision point lower than the package insert RI was evaluated for the Sebia assay, which improved risk stratification for patients with a low FLCr. The PC2 metric showed similar performance to the FLCr in models, without superior benefit. Conclusions The Sebia ELISA-based FLC assay can be employed in an MGUS risk stratification model with similar performance to the original 2005 risk stratification model using the FreeLite assay.
The State of Craniomaxillofacial Trauma Care in Low‐ and Middle‐Income Countries: A Scoping Review
Elwell, Zachary , Candelo, Estephanía , Srinivasan, Tarika , Zalaquett, Nader , Tuyishimire, Gratien, Ncogoza, Isaie , Jean-Gilles, Patrick, Legbo, J. N. , Tollefson, Travis T. , Zalaquett, Nader , Tuyishimire, Gratien , Ncogoza, Isaie , Legbo, Jacob Ndas , Tollefson, Travis , Shaye, David , Gomez, Estephania Candelo , Nuss, Sarah

Mayo Clinic

OTO Open | August 29, 2024 | Volume: 8 | Issue: 3 | Pages: No page available

10.1002/oto2.70000 | PMID 39211787 Get It

AbstractObjectiveThis scoping review aims to contribute a descriptive analysis of the craniomaxillofacial trauma (CMF trauma) literature in low‐ and middle‐income countries (LMICs) to identify knowledge gaps, direct future research, and inform policy.Data SourcesPubMed/MEDLINE, Cochrane Review, EMBASE, ClinicalTrials.gov, and Google Scholar from January 1, 2012 to December 10, 2023.Review MethodsThe Preferred Reporting Items for Systematic Reviews and Meta‐Analyses Extension for Scoping Reviews (PRISMA‐ScR) guided reporting, and the PRISMA flowchart documented database searches. Specific, predefined search terms and inclusion criteria were used for screening, and the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist was used for quality assessment. The search yielded 54 articles, with 13 meeting the inclusion criteria. Key findings were summarized and divided into 7 categories.ResultsThere were 10,420 patients (7739 [74.3%] male, 2681 [25.7%] female) with a male‐to‐female ratio of 2.9:1. The mean peak age of incidence of CMF trauma was 30.8 years, ranging from 20 to 40 years. Road traffic accidents were the leading cause (60.4%), followed by assault (27.2%) and falls (12.2%). The most common injuries were soft tissue injury (31.7%), isolated mandibular fracture (22.8%), and isolated middle‐third of mandible fracture (18.1%). The most common treatments were closed reduction and immobilization (29.5%), conservative management (27.6%), and open reduction and internal fixation (19.6%). Most patients (77.8%) experienced a treatment delay due to a lack of fixation materials (54.8%) or surgeon unavailability (35.7%).ConclusionCMF trauma remains a significant cause of global morbidity, yet there remains a lack of high‐quality, CMF trauma‐specific data in LMICs. Country‐specific investigations are required to enhance knowledge and inform novel interventions. Implementing policy change must be community‐specific and account for unique cultural barriers, attitudes, and behaviors to maximize patient care outcomes.
Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome
Lipton, Richard B. , Harriott, Andrea M. , Julia, Y., Smith, Jonathan H. , Stokes, Jonathan , Gandhi, Pranav , Jariwala‐Parikh, Krutika, Jensen, G., Trugman, Joel M. , Dodick, David W. , Lipton, R.B. , Ma, Julia Y, Jensen, Gabriel S, Dodick, David W

Mayo Clinic

Neurology | August 29, 2024 | Volume: 103 | Issue: 6 | Pages: No page available

10.1212/wnl.0000000000209745 | PMID 39197113 Get It

Reply by Authors
Hanchate, Kunal , Pathak, Ram A. , Thiel, David D. , Pak, Raymond , Maniaci, Michael, Lyon, Timothy D. , Lyon, Timothy D

Mayo Clinic

Urology Practice | August 28, 2024 | Volume: 11 | Issue: 6 | Pages: 980-981

10.1097/upj.0000000000000671 | PMID 39196669 Get It

Initial Experience With Inpatient Hospital Care at Home for Urologic Disease
Hanchate, Kunal , Pathak, Ram A. , Thiel, David D. , Pak, Raymond , Maniaci, Michael, Lyon, Timothy D. , Pak, Raymond W. , Lyon, Timothy D , Pak, Ray

Mayo Clinic

Urology Practice | August 28, 2024 | Volume: 11 | Issue: 6 | Pages: 975-981

10.1097/upj.0000000000000647 | PMID 39196663 Get It

mDia2 is an important mediator of MRTF-A-dependent regulation of breast cancer cell migration
Eder, Ian , Yu, Virginia, Antonello, Jacob , Chen, Fangyuan , Joy, Marion , Boone, David N. , Roy, Partha , Chen, Fangyuan , Roy, Partha , Chen, Fangyuan, Gau, David M. , Chawla, Pooja A. , Lucas, Peter C. , Lee, Adrian V.

Mayo Clinic

Molecular Biology of the Cell | August 28, 2024 | Volume: 35 | Issue: 10 | Pages: No page available

10.1091/mbc.e24-01-0008 | PMID 39196658 Get It

Dysregulated actin cytoskeleton gives rise to aberrant cell motility and metastatic spread of tumor cells. This study evaluates the effect of overexpression of wild-type versus functional mutants of MRTF-A on migration and invasion of breast cancer (BC) cells. Our studies indicate that SRF's interaction is critical for MRTF-A-induced promotion of both two-dimensional and three-dimensional cell migration, while the SAP-domain function is important selectively for three-dimensional cell migration. Increased MRTF-A activity is associated with more effective membrane protrusion, a phenotype that is attributed predominantly to SRF's interaction with MRTF. We demonstrate formin-family protein mDia2 as an important mediator of MRTF-stimulated actin polymerization at the leading edge and cell migration. Multiplexed quantitative immunohistochemistry and transcriptome analyses of clinical BC specimens further demonstrate a positive correlation between nuclear localization of MRTF with malignant traits of cancer cells and enrichment of MRTF–SRF gene signature in pair-matched distant metastases versus primary tumors. In conclusion, this study establishes a novel mechanism of MRTF-dependent regulation of cell migration and provides evidence for the association between MRTF activity and increased malignancy in human BC, justifying future development of specific small molecule inhibitors of the MRTF-SRF transcriptional complex as potential therapeutic agents in BC.
Psychosocial Health and the Association Between Cerebral Small Vessel Disease Markers With Dementia: The ARIC Study
Eswaran, Surabhee, Knopman, David S. , Koton, Silvia , Kucharska‐Newton, Anna , Liu, Albert C. , Liu, Chelsea , Lutsey, Pamela L. , Mosley, Thomas H. , Palta, Priya, Sharrett, A. Richey , Sullivan, Kevin , Groechel, Renée C. , Mosley, Thomas H. , Knopman, David S. , Kucharska-Newton, Anna M , Sullivan, Kevin J , Walker, Keenan A , Gottesman, Rebecca F , Groechel, Renee C , Lutsey, Pamela L , Walker, Keenan A. , Gottesman, Rebecca F.

Mayo Clinic

Stroke | August 28, 2024 | Volume: 55 | Issue: 10 | Pages: 2449-2458

10.1161/strokeaha.124.047455 | PMID 39193713 Get It

BACKGROUND: Associations between magnetic resonance imaging markers of cerebral small vessel disease (CSVD) and dementia risk in older adults have been established, but it remains unclear how lifestyle factors, including psychosocial health, may modify this association. METHODS: Social support and social isolation were assessed among participants of the community-based ARIC (Atherosclerosis Risk in Communities) Study, via self-reported questionnaires (1990–1992). Following categorization of both factors, participants were classified as having strong or poor mid-life social relationships. At visit 5 (2011–2013), participants underwent 3T brain magnetic resonance imaging quantifying CSVD measures: white matter hyperintensity volume, microbleeds (subcortical), infarcts (lacunar), and white matter integrity (diffusion tensor imaging). Incident dementia cases were identified from the time of imaging through December 31, 2020 with ongoing surveillance. Associations between CSVD magnetic resonance imaging markers and incident dementia were evaluated using Cox proportional-hazard regressions adjusted for demographic and additional risk factors (from visit 2). Effect modification by mid-life social relationships was evaluated. RESULTS: Of the 1977 participants with magnetic resonance imaging, 1617 participants (60.7% women; 26.5% Black participants; mean age at visit 2, 55.4 years) were examined. In this sample, mid-life social relationships significantly modified the association between white matter hyperintensity volume and dementia risk ( P interaction=0.001). Greater white matter hyperintensity volume was significantly associated with risk of dementia in all participants, yet, more substantially in those with poor (hazard ratio, 1.84 [95% CI, 1.49–2.27]) versus strong (hazard ratio, 1.26 [95% CI, 1.08–1.47]) mid-life social relationships. Although not statistically significant, subcortical microbleeds in participants with poor mid-life social relationships were associated with a greater risk of dementia, relative to those with strong social relationships, in whom subcortical microbleeds were no longer associated with elevated dementia risk. CONCLUSIONS: The elevated risk of dementia associated with CSVD may be reduced in participants with strong mid-life social relationships. Future studies evaluating psychosocial health through the life course and the mechanisms by which they modify the relationship between CSVD and dementia are needed.
Author’s Reply to Different Aortic Root Diameters on Echocardiography and MRI During Pregnancy in Mosaic Turner Syndrome
Majdalany, David , Lee, Hong Seok , Barry, Timothy , Singh, Katherine , Chapa, Jeff , Pettersson, Gösta , Majdalany, David S , Lee, Hong , Pettersson, Gosta B

Mayo Clinic

Korean Circulation Journal | August 28, 2024 | Volume: 54 | Issue: 11 | Pages: 762

10.4070/kcj.2024.2501 | PMID 39434364 Get It

Feasibility of structuring electronic health record data to facilitate real‐world data research: ICAREdata methods applied to multicenter cancer clinical trials
Campbell, Nancy , Hillman, Shauna L., Harlos, Elizabeth S., Stein, David , Chan, Miranda Y., Chow, Selina , Elrahi, Cassandra , Quina, Andre , Kokolus, Maeve C., Casagni, Michelle , Weiss, Matthias , Anderson, Daniel M. , Hoff, Olivia C., Rivera, Donna R. , Mandrekar, Sumithra J. , Piantadosi, Steven , Stadler, Walter M , Piantadosi, Steven , George, Suzanne , Campbell, Nancy, Stadler, Walter M. , Kluetz, Paul Gustav

Mayo Clinic

Cancer | August 28, 2024 | Volume: 131 | Issue: 1 | Pages: No page available

10.1002/cncr.35528 | PMID 39192753 Get It

AbstractBackgroundThe use of electronic health record (EHR) data for research is limited by a lack of structure and a standard data model. The objective of the ICAREdata (Integrating Clinical Trials and Real‐World Endpoints Data) project was to structure key research data elements in EHRs using a minimal Common Oncology Data Elements (mCODE) data model to extract and transmit data.MethodsThe ICAREdata project captured two EHR data elements essential to clinical trials: cancer disease status and treatment plan change. The project was implemented in clinical sites participating in Alliance for Clinical Trials in Oncology trials. Data were extracted from EHRs and sent by secure Fast Healthcare Interoperability Resource messaging (a standard for exchanging EHRs) to a database. Selected elements were compared with corresponding data from the trial's electronic data capture (EDC) system, Medidata Rave.ResultsBy December 2023, data were extracted and transmitted from 10 sites for 35 patients, involving 367 clinical encounters across 15 clinical trials. Data through March 2023 demonstrated that concordance for the elements treatment plan change and cancer disease status was 79% and 34%, respectively. When disease evaluation was reported by both EHR and EDC (n = 15), there was 87% agreement on cancer disease status.ConclusionsDocumentation, extraction, and aggregation of structured data elements in EHRs using mCODE and ICAREdata methods is feasible in multi‐institutional cancer clinical trials. EDC as a reference data set allowed assessment of the completeness of EHR data capture. Future initiatives will focus on elements with shared definitions in clinical and research environments and efficient workflows.Plain Language Summary Clinical trials use electronic case report forms to report data, and data must be manually entered on these forms, which is costly and time consuming. ICAREdata methods use structured, organized data from clinical trials that can be more easily shared instead having to enter free text into electronic health records.